About Us | A global leader in genomics - Illumina We are Illumina We are a global genomics and human health leader innovating the future of precision health We develop DNA sequencing and array-based life sciences technologies to enable boundless research discovery and personalized health
Illumina (ILMN) Moves to Strong Buy: Rationale Behind . . . - MSN Illumina (ILMN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy) This rating change essentially reflects an upward trend in earnings estimates -- one
Illumina, Other Genomics Fims Ramp Up Data Offerings for . . . NEW YORK – Illumina has long been content to supply as many sequencing reagents as the pharmaceutical industry could handle, but now the firm is willing to offer a more refined product: data Under plans for its new BioInsight business unit, announced in October, Illumina is willing to shoulder the burden of certain sequencing-intensive projects of interest to pharma, such as single-cell
Genomics products | Illumina Illumina offers a broad range of sequencing and microarray products for diverse genomic analysis applications
Statement Regarding Illumina’s Decision to Divest Grail Illumina’s decision to unwind its acquisition of Grail ensures the market for cancer detection tests remains competitive and delivers a choice of high-quality tests for patients and physicians, ultimately saving lives